SEC Form 4 · accession 0001501697-26-000065
X4 Pharmaceuticals, Inc · XFOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirske
Officer — Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501697
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jun 30, 2026 | S | 8,543 | $4.2641 | D | 167,750 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Of the shares of common stock reported, 96,627 shares represent restricted stock units.